Which has preferable valuation and earnings, TRAX or RCKT?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is TRAX or RCKT more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media prefer TRAX or RCKT?

In the previous week, First Tracks Biotherapeutics and First Tracks Biotherapeutics both had 4 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat First Tracks Biotherapeutics' score of 0.51 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RCKT or INBX more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -52.77% -44.92% Inhibrx Biosciences N/A -563.90% -83.48%

Does the media favor RCKT or INBX?

In the previous week, Inhibrx Biosciences had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for Inhibrx Biosciences and 4 mentions for Rocket Pharmaceuticals. Inhibrx Biosciences' average media sentiment score of 1.49 beat Rocket Pharmaceuticals' score of 1.00 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NVAX or RCKT?

In the previous week, Novavax had 27 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 31 mentions for Novavax and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat Novavax's score of 0.21 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 6 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ORIC or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is ORIC or RCKT more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media refer more to ORIC or RCKT?

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat Oric Pharmaceuticals' score of 0.95 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, AVBP or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is AVBP or RCKT more profitable?

ArriVent BioPharma's return on equity of -50.26% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -50.26% -46.66% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media refer more to AVBP or RCKT?

In the previous week, ArriVent BioPharma had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for ArriVent BioPharma and 4 mentions for Rocket Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 1.46 beat Rocket Pharmaceuticals' score of 1.00 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Rocket Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rocket Pharmaceuticals (RCKT) Competitors

$3.75 -0.11 (-2.85%)

As of 02:40 PM Eastern

Compare

RCKT vs. TRAX, INBX, NVAX, ORIC, and AVBP

Should you buy Rocket Pharmaceuticals stock or one of its competitors? Rocket Pharmaceuticals's main competitors and comparable companies include First Tracks Biotherapeutics (TRAX), Inhibrx Biosciences (INBX), Novavax (NVAX), Oric Pharmaceuticals (ORIC), and ArriVent BioPharma (AVBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rocket Pharmaceuticals compare to First Tracks Biotherapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, First Tracks Biotherapeutics and First Tracks Biotherapeutics both had 4 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat First Tracks Biotherapeutics' score of 0.51 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

First Tracks Biotherapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 47.23%. Rocket Pharmaceuticals has a consensus target price of $8.57, suggesting a potential upside of 128.57%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

First Tracks Biotherapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Summary

Rocket Pharmaceuticals beats First Tracks Biotherapeutics on 7 of the 11 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Inhibrx Biosciences?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Inhibrx Biosciences had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for Inhibrx Biosciences and 4 mentions for Rocket Pharmaceuticals. Inhibrx Biosciences' average media sentiment score of 1.49 beat Rocket Pharmaceuticals' score of 1.00 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Inhibrx Biosciences	$1.30M	1,390.47	-$140.05M	-$8.88	N/A

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rocket Pharmaceuticals presently has a consensus price target of $8.57, suggesting a potential upside of 128.57%. Inhibrx Biosciences has a consensus price target of $197.50, suggesting a potential upside of 60.83%. Given Rocket Pharmaceuticals' higher probable upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Rocket Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, suggesting that its share price is 266% more volatile than the broader market.

Rocket Pharmaceuticals' return on equity of -52.77% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Summary

Rocket Pharmaceuticals and Inhibrx Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Novavax had 27 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 31 mentions for Novavax and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat Novavax's score of 0.21 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	6 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Novavax presently has a consensus target price of $14.00, suggesting a potential upside of 39.30%. Rocket Pharmaceuticals has a consensus target price of $8.57, suggesting a potential upside of 128.57%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Rocket Pharmaceuticals has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

53.0% of Novavax shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Novavax has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	4.01	$440.30M	-$1.52	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Summary

Novavax beats Rocket Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat Oric Pharmaceuticals' score of 0.95 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Oric Pharmaceuticals presently has a consensus target price of $19.45, indicating a potential upside of 53.06%. Rocket Pharmaceuticals has a consensus target price of $8.57, indicating a potential upside of 128.57%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Oric Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Rocket Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oric Pharmaceuticals' return on equity of -35.35% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Summary

Oric Pharmaceuticals beats Rocket Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, ArriVent BioPharma had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for ArriVent BioPharma and 4 mentions for Rocket Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 1.46 beat Rocket Pharmaceuticals' score of 1.00 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma presently has a consensus target price of $44.86, suggesting a potential upside of 47.02%. Rocket Pharmaceuticals has a consensus target price of $8.57, suggesting a potential upside of 128.57%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ArriVent BioPharma has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

ArriVent BioPharma's return on equity of -50.26% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Summary

ArriVent BioPharma beats Rocket Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$411.68M	$4.02B	$7.26B	$12.91B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-22.06	12.64	273.83	25.42
Price / Sales	N/A	1,362.02	676.21	123.96
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	1.12	16.28	12.89	6.17
Net Income	-$223.12M	-$22.72M	$3.48B	$349.24M
7 Day Performance	3.59%	-1.62%	-0.36%	-1.42%
1 Month Performance	9.97%	10.88%	6.49%	2.53%
1 Year Performance	12.95%	53.32%	25.06%	15.84%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	3.3091 of 5 stars	$3.75 -2.8%	$8.57 +128.6%	+19.1%	$411.68M	N/A	N/A	240	Analyst Forecast
TRAX First Tracks Biotherapeutics	3.4399 of 5 stars	$43.28 +0.4%	$63.00 +45.6%	N/A	$1.54B	N/A	N/A	N/A	Analyst Forecast
INBX Inhibrx Biosciences	3.0206 of 5 stars	$104.94 +1.3%	$197.50 +88.2%	+352.5%	$1.53B	$1.30M	N/A	166	Positive News
NVAX Novavax	1.9149 of 5 stars	$8.86 -0.9%	$14.00 +58.0%	+36.7%	$1.47B	$413.80M	N/A	1,990
ORIC Oric Pharmaceuticals	3.1114 of 5 stars	$13.46 -5.2%	$19.45 +44.5%	+26.5%	$1.47B	N/A	N/A	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. TRAX, INBX, NVAX, ORIC, and AVBP

How does Rocket Pharmaceuticals compare to First Tracks Biotherapeutics?

Summary

How does Rocket Pharmaceuticals compare to Inhibrx Biosciences?

Summary

How does Rocket Pharmaceuticals compare to Novavax?

Summary

How does Rocket Pharmaceuticals compare to Oric Pharmaceuticals?

Summary

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. TRAX, INBX, NVAX, ORIC, and AVBP

How does Rocket Pharmaceuticals compare to First Tracks Biotherapeutics?

Do institutionals and insiders have more ownership in TRAX or RCKT?

Does the media prefer TRAX or RCKT?

Do analysts recommend TRAX or RCKT?

Which has preferable valuation and earnings, TRAX or RCKT?

Is TRAX or RCKT more profitable?

Summary

How does Rocket Pharmaceuticals compare to Inhibrx Biosciences?

Does the media favor RCKT or INBX?

Which has stronger earnings and valuation, RCKT or INBX?

Do institutionals & insiders have more ownership in RCKT or INBX?

Do analysts rate RCKT or INBX?

Which has more volatility & risk, RCKT or INBX?

Is RCKT or INBX more profitable?

Summary

How does Rocket Pharmaceuticals compare to Novavax?

Does the media refer more to NVAX or RCKT?

Which has more risk and volatility, NVAX or RCKT?

Do analysts rate NVAX or RCKT?

Is NVAX or RCKT more profitable?

Do institutionals and insiders have more ownership in NVAX or RCKT?

Which has better valuation and earnings, NVAX or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Oric Pharmaceuticals?

Does the media refer more to ORIC or RCKT?

Which has higher earnings & valuation, ORIC or RCKT?

Do analysts prefer ORIC or RCKT?

Which has more volatility & risk, ORIC or RCKT?

Do institutionals and insiders believe in ORIC or RCKT?

Is ORIC or RCKT more profitable?

Summary

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

Does the media refer more to AVBP or RCKT?

Do analysts recommend AVBP or RCKT?

Which has preferable valuation & earnings, AVBP or RCKT?

Do insiders & institutionals have more ownership in AVBP or RCKT?

Which has more volatility & risk, AVBP or RCKT?

Is AVBP or RCKT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools